[
    [
        {
            "time": "2020-12-27",
            "original_text": "【浙商医药|周报】CXO 龙头新思考：高估值下，加仓源于什么？ ──医药外包行业周报20201227",
            "features": {
                "keywords": [
                    "CXO",
                    "龙头",
                    "高估值",
                    "加仓",
                    "医药外包"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【浙商医药|周报】CXO 龙头新思考：高估值下，加仓源于什么？ ──医药外包行业周报20201227",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]